Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

John Johnson

TitleResident Physician
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentIMSL Integrated Medicine, College of Integrated Clinical Enterprise
DivisionRegional Programs
Address1601 West 40th
Mail Slot # 599
Pine Bluff AR 71603
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 01; 20(19):4994-5000. PMID: 25096067.
      View in: PubMed
    2. Cohen MH, Johnson JR, Justice R, Pazdur R. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors. Oncologist. 2012; 17(7):992-7. PMID: 22643537.
      View in: PubMed
    3. Cohen MH, Johnson JR, Justice R, Pazdur R. Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval. Oncologist. 2011; 16(12):1762-70. PMID: 22089970.
      View in: PubMed
    4. Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, Sridhara R, Pazdur R. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010; 15(12):1344-51. PMID: 21148614.
      View in: PubMed
    5. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst. 2010 Feb 24; 102(4):230-43. PMID: 20118413.
      View in: PubMed
    6. Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008 Jun; 13(6):709-14. PMID: 18586926.
      View in: PubMed
    7. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park). 2007 Dec; 21(14):1696-706; discussion 1706-9, 1712, 1715. PMID: 18247017.
      View in: PubMed
    8. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007 Oct; 12(10):1247-52. PMID: 17962618.
      View in: PubMed
    9. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R, Pazdur R. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007 Apr 15; 13(8):2318-22. PMID: 17438089.
      View in: PubMed
    10. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007 Jan; 47(1):78-86. PMID: 17192505.
      View in: PubMed
    11. Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD, Abraham S, Booth BP, Goheer MA, Morse D, Chen XH, Chidambaram N, Kenna L, Gobburu JV, Justice R, Pazdur R. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2006 Sep 15; 12(18):5329-35. PMID: 17000665.
      View in: PubMed
    12. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6767-71. PMID: 16203762.
      View in: PubMed
    13. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15; 11(18):6414-21. PMID: 16166415.
      View in: PubMed
    14. Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res. 2005 Aug 15; 11(16):5671-7. PMID: 16115902.
      View in: PubMed
    15. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005 Aug; 10(7):461-6. PMID: 16079312.
      View in: PubMed
    16. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist. 2005 Jun-Jul; 10(6):363-8. PMID: 15967829.
      View in: PubMed
    17. Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005 Feb 01; 11(3):982-92. PMID: 15709163.
      View in: PubMed
    18. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res. 2005 Jan 01; 11(1):12-9. PMID: 15671523.
      View in: PubMed
    19. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004; 9(5):482-8. PMID: 15477632.
      View in: PubMed
    20. Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res. 2003 Jun; 9(6):1972-9. PMID: 12796358.
      View in: PubMed
    21. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003 Apr 01; 21(7):1404-11. PMID: 12663734.
      View in: PubMed
    22. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002 May; 8(5):935-42. PMID: 12006504.
      View in: PubMed
    23. Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin Cancer Res. 2002 Mar; 8(3):665-9. PMID: 11895893.
      View in: PubMed
    24. Binienda Z, Beaudoin MA, Thorn BT, Prapurna DR, Johnson JR, Fogle CM, Slikker W, Ali SF. Alteration in Electroencephalogram and Monoamine Concentrations in Rat Brain following Ibogaine Treatment. Ann N Y Acad Sci. 1998 May; 844(1):265-273. PMID: 29090814.
      View in: PubMed
    Johnson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _